智通财经APP获悉，百奥赛图-B(02315)再涨超10%，截至发稿，涨8.58%，报45.56港元，成交额6619.52万港元。
消息面上，百奥赛图近期发布2025年度业绩预告，预期归母净利润1.62亿元至1.82亿元，同比增加384.26%到443.88%。公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增长。高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水平得以快速提高。
国联民生证券表示，2025年以来，公司与多家国内外头部药企达成对外授权，并有多条管线获得IND批准，随着授权管线的推进，公司有望获得里程碑付款等收入，进一步打开增长天花板，对外授权包括：2025年7月，公司与百济神州达成抗体分子的全球许可协议，百济神州在全人抗体平台的授权基础上将合作拓展至抗体分子授权许可领域；2025年9月，公司与默克达成RenMice平台自主开发的全人抗体的授权，将用于开发抗体偶联LNP。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.